SymBio's ¥6.77bn EVO Fund Deal Could More Than Double Its Share Count
SymBio Pharmaceuticals lined up an estimated ¥6.77bn from Cayman fund EVO Fund to keep its antiviral drug trials funded through March 2028, but the bond-and-warrant structure could swell its share count by more than 125% if every warrant is exercised.